Loading...
skip to Main Content

- - Reading time:

2021 Retrospective

Click and navigate through our interactive timeline. 

Another year: 12 months of outstanding achievements and challenges met! Follow us through EASL’s highlights of 2021. 

January

EASL started 2021 motivated and ready to serve the community of the Home of Hepatology!

February

March

For this last month of winter, EASL connected with the community through:

April

April witnessed a lot of firsts.

May

May was a lively month 

June

EASL entered the most intense period of the year: the ILC month

  • ILC 2021, held digitally, brought together 6,340 delegates from 111 countries. The congress hosted 155 sessions, including 13 EASL Studio Sessions, live from EASL’s temporary Home of Hepatology at Domaine de Choully in Geneva. We also introduced Livy as EASL’s official mascot.
  • At the 2021 General Assembly, Phil Newsome handed over the role of Secretary General to Thomas Berg. Aleksander Krag was elected as Vice-Secretary and Virginia Hernandez-Gea and Jean-Charles Nault replaced Maria Reig and Pierre-Emmanuel Rautou on the Scientific Committee.
  • The Journal of Hepatology achieved unprecedented results with a 2020 impact factor of 25.083, up from the 2019 score of 20.582. JHEP Reports was accepted for indexing by PubMed Central and Scopus.

July

While Livy and most of the community were enjoying some well-deserved R&R, the Journal of Hepatology published the EASL Position Paper: Systemic treatment of hepatocellular carcinoma, by Jordi Bruix et al.

August

Through the sunny month of August, we ran EASL’s Open Letter campaign with 10 asks to improve liver cancer care. If you haven’t done so, you can still sign the letter here!

September

Back to school!

  • Starting with the clinical school in Frankfurt, Germany, on Management of acute-on-chronic liver failure jointly organised by EASL and ERN.
  • Almost 500 delegates joined us online to explore the latest scientific developments in NAFLD and NASH during NAFLD Summit 2021.

October

The autumn was a flurry of EASL activities.

  • The monothematic conference on Bleeding, Thrombosis, and Vascular Liver Diseases was held both online and in-person in Geneva. Read about it here. In partnership with AALSD, we hosted the EASL-AASLD Endpoints meeting.
  • EASL contributed to Liver Cancer Awareness Month through high-level advocacy events with key policymakers:
  • Beating liver cancer in Europe – the empowerment of prevention and early detection was co-organised with the European Liver Patients’ Association (ELPA), under the patronage of the Slovenian presidency of the Council of the European Union
  • The very first episode of EASL Studio, was launched and dedicated to liver cancer awareness month. This first live edition attracted over 500 viewers from 63 countries. Catch up with the other EASL Studio episodes here.

November

  • The final EASL School of the year Progress, pitfalls, and challenges in the management of portal hypertension took place in Barcelona.
  • Key findings of a jointly run survey together with ESOT, ELITA, and ILTS were published in November. The survey, sent to 470 centres, set out to explore how patients, healthcare professionals, and liver transplant centres across the world were affected by COVID-19 in their clinical care and waiting-list management.
  • To finish up the month, we gathered representatives from liver patient associations for the EASL Patient Forum 2021: Health literacy to empower patients and address inequities.

December

  • This last month of the year started with a major advocacy milestone: The EASL–Lancet Liver Commission which marked the publication of the report of the EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
  • 2021 ended on a fun note with EASL’s Festive Season Calendar. Follow Livy and take the 24 mini-challenges that await you here.

How about you? What have been your achievements this year? Comment below and share your 2021 highlights with us!

This Post Has 0 Comments

Leave a Reply

Your email address will not be published.

Back To Top